Clinical trials
Bone Diseases, Metabolic trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2006 | 2 |
| 2009 | 3 |
| 2010 | 2 |
| 2012 | 3 |
| 2015 | 2 |
| 2019 | 3 |
| 2021 | 4 |
| 2022 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Recruiting | 4 |
| Terminated | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Centre Hospitalier Universitaire de Saint Etienne | 3 |
| Amgen | 2 |
| Institut National de la Santé Et de la Recherche Médicale, France | 2 |
| University Hospital, Montpellier | 2 |
| AstraZeneca | 1 |
| CHU de Reims | 1 |
| Centre Hospitalier Régional d'Orléans | 1 |
| Centre Hospitalier Universitaire, Amiens | 1 |
| Direction Centrale du Service de Santé des Armées | 1 |
| Eli Lilly and Company | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bone Diseases, Metabolic | 24 |
| Osteoporosis | 10 |
| Breast Neoplasms | 3 |
| Osteoporosis, Postmenopausal | 2 |
| Sarcopenia | 2 |
| Anemia, Sickle Cell | 1 |
| Ankylosis | 1 |
| Anorexia Nervosa | 1 |
| Arthritis, Rheumatoid | 1 |
| Bone Diseases | 1 |
Trials
Showing 76 to 24 of 24. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.